Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792804 | 0.86 | ALOX5AP (0.35) | MAPTALOX5APRAPGEF4HASPIN | |
| SCHEMBL22792465 | 0.81 | MAPT (0.44) | MAPTAOC3KCNH2CYP19A1HASPIN | |
| SCHEMBL22793033 | 0.81 | ALOX5AP (0.38) | MAPTALOX5APAOC3KCNH2CYP19A1 | |
| SCHEMBL26596994 | 0.79 | ALOX5AP (0.40) | MAPTALOX5APAOC3KCNH2CYP19A1 | |
| SCHEMBL22792640 | 0.77 | DHFR (0.46) | MAPTAOC3KCNH2CYP19A1RAPGEF4 | |
| SCHEMBL30194606 | 0.70 | NR1H2 (0.39) | — | |
| SCHEMBL23478921 | 0.70 | ATM (0.38) | MAPTCYP19A1RAPGEF4HASPINTOP2A | |
| SCHEMBL16449989 | 0.68 | KCNH2 (0.41) | MAPTKCNH2 | |
| SCHEMBL22792909 | 0.67 | DHFR (0.46) | RAPGEF4HASPIN | |
| SCHEMBL12775610 | 0.66 | CYP17A1 (0.41) | MAPTCYP19A1RAPGEF4HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | MAPT 4336/4885ALOX5AP 2853/4885AOC3 4083/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | MAPT 4283/4885ALOX5AP 2534/4885AOC3 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.